Literature DB >> 20456622

Is obesity a further cardiovascular risk factor in patients with erectile dysfunction?

Giovanni Corona1, Matteo Monami, Valentina Boddi, Daniela Balzi, Cecilia Melani, Nelli Federico, Daniela Balzi, Alessandra Sforza, Carlo M Rotella, Gianni Forti, Edoardo Mannucci, M Maggi.   

Abstract

INTRODUCTION: Erectile dysfunction (ED) and, in particular, arteriogenic ED have been proposed as new markers of risk for incident major adverse cardiovascular events (MACE). Reduced penile blood flow is more common in obese people than in leaner ED subjects. AIM: To explore the interaction of overweight/obesity and penile blood flow in the prediction of incident MACE.
METHODS: This is an observational prospective cohort study evaluating a consecutive series of 1,687 patients attending our andrological unit for ED. Different clinical, biochemical, and instrumental (penile flow at color Doppler ultrasound: PCDU) parameters were evaluated. MAIN OUTCOMES MEASURES: According to body mass index (BMI), subjects were divided into three groups: normal weight (BMI = 18.5-24.9 kg/m(2)), overweight (BMI = 25.0-29.9 kg/m(2)), and obese (BMI >or= 30.0 kg/m(2)). Information on MACE was obtained through the City of Florence Registry Office.
RESULTS: Among patients studied, 39.8% were normal weight, while 44.1% and 16.1% showed BMI 25-29.9 and 30 kg/m(2) or higher, respectively. During a mean follow-up of 4.3 +/- 2.6 years, 139 MACE, 15 of which were fatal, were observed. Cox regression model, after adjusting for age and Chronic Diseases Score, showed that obesity classes along with the presence of arteriogenic ED (peak systolic velocity at PCDU <25 cm/second) were significantly and independently associated with incident MACE (hazard ratio = 1.47 [1.1-1.95], P < 0.05 and 2.58 [1.28-5.09], P < 0.001, respectively). When a separate analysis was performed for classes of obesity, reduced peak systolic velocity at PCDU (<25 cm/second) was significantly associated with incident MACE in obese (BMI >or= 30 kg/m(2)), but not in leaner, subjects.
CONCLUSIONS: In obese subjects, more than in leaner ED subjects, impaired penile blood flow is associated with an increased risk of incident cardiovascular disease. The interaction with concomitant risk factors, such as obesity, should be taken into account when assessing the predictive value of penile blood flow for cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456622     DOI: 10.1111/j.1743-6109.2010.01839.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  [News from andrology. Infertility, erectile dysfunction, and hypogonadism].

Authors:  W Weidner; A Rusz; A Pilatz; A Hauptmann; H-C Schuppe
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  Testosterone and cardiovascular risk in patients with erectile dysfunction.

Authors:  G Corona; G Rastrelli; G Balercia; A Sforza; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-11-08       Impact factor: 4.256

Review 3.  The Association of Erectile Dysfunction and Cardiovascular Disease: A Systematic Critical Review.

Authors:  Omer A Raheem; Jeannie J Su; Joel R Wilson; Tung-Chin Hsieh
Journal:  Am J Mens Health       Date:  2016-02-04

Review 4.  Erectile dysfunction and central obesity: an Italian perspective.

Authors:  Giovanni Corona; Giulia Rastrelli; Sandra Filippi; Linda Vignozzi; Edoardo Mannucci; Mario Maggi
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

5.  Phosphorus as predictive factor for erectile dysfunction in middle aged men: A cross sectional study in Korea.

Authors:  Seung Ki Min; Kwibok Choi; Soon Ki Kim; Gyeong In Lee; In-Chang Cho
Journal:  Investig Clin Urol       Date:  2016-10-28

Review 6.  Treatment of Functional Hypogonadism Besides Pharmacological Substitution.

Authors:  Giovanni Corona; Giulia Rastrelli; Annamaria Morelli; Erica Sarchielli; Sarah Cipriani; Linda Vignozzi; Mario Maggi
Journal:  World J Mens Health       Date:  2019-08-29       Impact factor: 5.400

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.